Incyte Corporation (INCY)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
82.44+0.54 (+0.66%)
At close: 4:00 PM EDT
People also watch:
VRTXBMRNMYGNALXNREGN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open81.55
Prev Close81.90
Bid81.66 x 100
Ask87.00 x 100
Day's Range81.55 - 87.98
52wk Range55.00 - 133.62
1y Target EstN/A
Market Cap15.5B
P/E Ratio (ttm)224.02
Beta0.65
Volume3,220,278
Avg Vol (3m)1,120,825
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Biotech Stocks Seesaw As M&A Hopes Meet New Pricing Fears
    Investor's Business Daily8 hours ago

    Biotech Stocks Seesaw As M&A Hopes Meet New Pricing Fears

    The biotech group hit a seven-month high Wednesday before reversing after Hillary Clinton attacked drug pricing again.

  • Barrons.com14 hours ago

    [$$] Smaller Biotech Buyout Targets After Medivation

    Gabelli & Co. On Monday, Pfizer announced that it had agreed to acquire Medivation for $81.50 per share in cash, or $14 billion of total enterprise value. The price represents a 21% premium to Medivation’s (MDVN) previous closing share price. Pfizer (PFE) hosted a conference call after the announcement.

  • Barrons.com2 days ago

    4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss

    Yesterday, we highlighted six stocks that the folks at Citigroup contend could be buyout targets following Pfizer's (PFE) $14 billion purchase of Medivation (MDVN). Today, Gabelli's Jing He offers four ...